Abstract
A chimeric protein consisting of the N-terminal domain of lipopolysaccharide-binding protein and the C-terminal domain of bactericidal/permeability-increasing protein demonstrated a dose-dependent survival benefit (P = 0.001) and reduced endotoxin levels (P < 0.01) in neutropenic rats with Pseudomonas aeruginosa sepsis. This lipopolysaccharide-binding protein-bactericidal/ permeability-increasing peptide has favorable pharmacokinetics and antiendotoxin properties which may be of value for human sepsis.
MeSH terms
-
Acute-Phase Proteins*
-
Animals
-
Antimicrobial Cationic Peptides
-
Blood Proteins / pharmacokinetics
-
Blood Proteins / therapeutic use*
-
Carrier Proteins / pharmacokinetics
-
Carrier Proteins / therapeutic use*
-
Cell Membrane / metabolism
-
Colony Count, Microbial
-
Endotoxins / analysis
-
Female
-
Limulus Test
-
Membrane Glycoproteins*
-
Membrane Proteins*
-
Neutropenia / complications
-
Pseudomonas Infections / drug therapy*
-
Pseudomonas Infections / microbiology
-
Pseudomonas aeruginosa / drug effects
-
Rats
-
Rats, Sprague-Dawley
-
Recombinant Fusion Proteins / pharmacokinetics
-
Recombinant Fusion Proteins / therapeutic use
-
Sepsis / drug therapy*
-
Sepsis / metabolism
-
Sepsis / microbiology
Substances
-
Acute-Phase Proteins
-
Antimicrobial Cationic Peptides
-
Blood Proteins
-
Carrier Proteins
-
Endotoxins
-
Membrane Glycoproteins
-
Membrane Proteins
-
Recombinant Fusion Proteins
-
bactericidal permeability increasing protein
-
lipopolysaccharide-binding protein